Over two decades of research into the cellular mechanisms underlying Lowe syndrome have led to the identification of a potential therapeutic strategy for this rare genetic disorder, which affects the eyes, nervous system and kidneys. The findings are described in a study published in Signal Transduction and Targeted Therapy, by the research group led by Antonella De Matteis, coordinator of the Cell Biology Program at the Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli and full professor of cell biology at the University of Naples Federico II in the Department of Molecular Medicine and Medical Biotechnology.